The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: A review
| Autor: | Eric Lechevallier, Gilles Karsenty, Nicolas Branger, Romain Boissier, Jennifer Campagna |
|---|---|
| Přispěvatelé: | Chirurgie urologique et transplantation rénale [Hôpital de la Conception - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Vascular research center of Marseille (VRCM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Comité de Cancérologie (CCAFU), Association Française d'Urologie, Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM) |
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Prognostic factor medicine.medical_specialty Neutrophils Urology Lymphocyte 030232 urology & nephrology Locally advanced [SDV.CAN]Life Sciences [q-bio]/Cancer Disease urologic and male genital diseases [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology 03 medical and health sciences 0302 clinical medicine Renal cell carcinoma Internal medicine medicine Humans Lymphocytes business.industry fungi Hazard ratio Cancer Nomogram Prognosis medicine.disease Kidney Neoplasms 3. Good health medicine.anatomical_structure 030220 oncology & carcinogenesis business |
| Zdroj: | Urologic Oncology: Seminars and Original Investigations Urologic Oncology: Seminars and Original Investigations, Elsevier, 2017, pp.135-141. ⟨10.1016/j.urolonc.2017.01.016⟩ Urologic Oncology: Seminars and Original Investigations, 2017, pp.135-141. ⟨10.1016/j.urolonc.2017.01.016⟩ |
| ISSN: | 1078-1439 |
| DOI: | 10.1016/j.urolonc.2017.01.016 |
| Popis: | Background The neutrophil-lymphocyte ratio (NLR) is a biological marker of inflammation with a significant prognostic value in the field of oncology. Aim In this review, we discuss the prognostic value of the NLR in renal cell carcinoma (RCC). Material and Method We conducted a literature review of the PubMed database in August 2016. Initial research identified 31 publications. Following full-text screening, 15 studies were finally included: 7 studies concerning metastatic or locally advanced renal cancer, 6 studies dealing with localized renal cancer, 2 articles evaluating the NLR in renal cancer whatever the status of the disease (metastatic or localized). Results For localized RCC, an NLR o 3 was predictive of a reduced risk of recurrence (hazard ratio ¼ 1.63 [1.15, 2.29]). The prognostic value of the NLR was stronger for metastatic or locally advanced RCC. An NLR o 3 predicted increased overall survival (hazard ratio ¼ 1.55 [1.36, 1.76]), progression-free survivals (hazard ratio ¼ 3.19 [2.23, 4.57]), and a response to systemic treatment. Conclusion In current practice, the NLR is a simple and inexpensive prognostic factor with potential improvement in the prognostic performance of nomograms used in renal oncology. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect